Reivindicaciones
1. A method for obtaining data useful for the prognosis of an autoimmune disease which comprises detecting genetic polymorphisms rs35643203, rs71575932 and/or rs7755568 of the "vasoactive intestinal peptide" (VIP ) gene in a biological sample isolated from a subject suffering from an autoimmune disease. 2. The method according to claim 1, which further comprises detecting genetic polymorphism rs3823082 and/or rs688136 of theVIP gene. 3. The method according to claim 2, which further comprises detecting at least one of the genetic polymorphisms of theVIP gene selected from the list comprising: rs12213214, rs60946248, rs140023105, rs7764067, rs12201030, rs74760293, rs149081483 and rs12201140, or any of the combinations thereof. 4. The method according to any of claims 1 to 3, where the autoimmune disease is selected from the list comprising: autoimmune arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. 5. The method according to claim 4, where the autoimmune arthritis is rheumatoid arthritis. 6. The method according to any of claims 1 to 5, where the biological sample is blood, serum, plasma, saliva, urine, synovial fluid or lymph. 7. The method according to any of claims 1 to 6, where the subject is a human. 8. Anin vitro method for the prognosis of an autoimmune disease in a subject suffering from an autoimmune disease, which comprises: a. detecting genetic polymorphisms rs35643203, rs71575932 and/or rs7755568 of theVIP gene in a biological sample; and b. associating the T allele of genetic polymorphism rs35643203, associating the G allele of genetic polymorphism rs71575932 and/or associating the A allele of polymorphism rs7755568, with a poor prognosis. 9. The method according to claim 8, which further comprises in step (a) detecting polymorphism rs3823082 and/or rs688136 of theVIP gene and in step (b) associating the TT genotype of polymorphism rs3823082 with a poor prognosis and/or associating the CC genotype of polymorphism rs688136 with a good prognosis. 10. The method according to claim 9, which further comprises detecting in step (a) at least one of the genetic polymorphisms of theVIP gene selected from the list comprising rs12213214, rs60946248, rs140023105, rs7764067, rs12201030, rs74760293, rs149081483 and rs12201140, or any of the combinations thereof, and associating in step (b) the A allele of polymorphism rs12213214, the T allele of polymorphism rs60946248, the G allele of polymorphism rs140023105, the T allele of polymorphism rs7764067, the G allele of polymorphism rs12201030, the C allele of polymorphism rs74760293, the G allele of polymorphism rs149081483 and the T allele of polymorphism rs12201140, or any of the combinations thereof, with a poor prognosis. 11. The method according to any of claims 8 to 10, where furthermore anti-citrullinated protein antibodies are detected in a step (c). 12. The method according to any of claims 8 to 11, where the autoimmune disease is selected from the list comprising: autoimmune arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. 13. The method according to claim 12, where the autoimmune arthritis is rheumatoid arthritis. 14. The method according to any of claims 8 to 13, where the biological sample is blood, plasma, serum, saliva, urine, synovial fluid or lymph. 15. The method according to any of claims 8 to 14 where the subject is a human. 16. Anin vitro method for designing a personalized treatment for a subject suffering from an autoimmune disease which comprises detecting genetic polymorphisms rs35643203, rs71575932 and/or rs7755568 of theVIP gene in the biological sample, wherein the presence of the T allele of genetic polymorphism rs35643203, the presence of the G allele of genetic polymorphism rs71575932 and/or the presence of the A allele of polymorphism rs7755568 is indicative that the treatment to be administered is a combined therapy of synthetic and biological disease-modifying drugs (DMDs). 17. The method according to claim 16, which further comprises detecting polymorphism rs3823082 and/or rs688136 of theVIP gene and where the presence of the TT genotype of polymorphism rs3823082 is indicative that the treatment to be administered is said combined therapy and/or the presence of the CC genotype of polymorphism rs688136 is indicative that the treatment to be administered is a monotherapy of non-biological DMD. 18. The method according to claim 17, which further comprises detecting the polymorphism of theVIP gene selected from the list comprising rs12213214, rs60946248, rs140023105, rs7764067, rs12201030, rs74760293, rs149081483 and rs12201140, or any of the combinations thereof; and where the presence of the A allele of polymorphism rs12213214, the T allele of polymorphism rs60946248, the G allele of polymorphism rs140023105, the T allele of polymorphism rs7764067, the A allele of polymorphism rs7755568, the C allele of polymorphism rs74760293, the G allele of polymorphism rs149081483 and the T allele of polymorphism rs12201140, or any of the combinations thereof, is indicative that the treatment to be administered is said combined therapy and/or the presence of the G allele of polymorphism rs12201030 is indicative that the treatment to be administered is a monotherapy of non-biological DMD. 19. The method according to any of claims 16 to 18, where the autoimmune disease is selected from the list comprising: autoimmune arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. 20. The method according to claim 19, where the autoimmune arthritis is rheumatoid arthritis. 21. The method according to any of claims 16 to 20, where the biological sample is blood, plasma, serum, saliva, urine, synovial fluid or lymph. 22. The method according to any of claims 16 to 21, where the biological DMD is a tumor necrosis factor blocking agent. 23. The method according to any of claims 16 to 22, where the subject is a human. 24. Use of genetic polymorphisms rs35643203, rs71575932 and/or rs7755568 of theVIP gene as a prognostic marker of an autoimmune disease in a subject suffering from an autoimmune disease. 25. Use according to claim 24, further comprising the use of genetic polymorphism rs3823082 and/or rs688136 of theVIP gene. 26. Use according to claim 25, further comprising the use of genetic polymorphisms of theVIP gene selected from the list comprising: rs12213214, rs60946248, rs140023105, rs7764067, rs12201030, rs74760293, rs149081483 and rs12201140, or any of the combinations thereof. 27. Use according to any of claims 24 to 26, where the autoimmune disease is selected from the list comprising: autoimmune arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. 28. Use according to claim 27, where the autoimmune arthritis is rheumatoid arthritis. 29. Use according to any of claims 24 to 28, where the subject is a human. 30. A kit comprising primers and/or probes for detecting genetic polymorphisms rs35643203, rs71575932 and/or rs7755568 of theVIP gene. 31. The kit according to claim 30, further comprising primers and/or probes for detecting genetic polymorphism rs3823082 and/or rs688136 of theVIP gene. 32. The kit according to claim 31, further comprising primers and/or probes detecting genetic polymorphisms rs12213214, rs60946248, rs140023105, rs7764067, rs12201030, rs74760293, rs149081483 and rs12201140 of the VIP gene, or any of the combinations thereof. 33. The kit according to any of claims 30 to 32, further comprising antibodies, probes or primers specific for detecting anti-citrullinated protein antibodies or citrullinated peptides or citrullinated proteins. 34. Use of the kit according to any of claims 30 to 33 for the prognosis of an autoimmune disease in a subject suffering from said disease. 35. Use according to claim 34, where the autoimmune disease is selected from the list comprising: autoimmune arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. 36. Use according to claim 35, where the autoimmune arthritis is rheumatoid arthritis. 37. Use according to any of claims 34 to 36, where the subject is a human.
